AM Best Affirms Credit Ratings of Ping An Property & Casualty Insurance Company of China, Ltd
HONG KONG--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of 'a+' (Excellent) of Ping An Property & Casualty Insurance Company of China, Ltd (Ping An P&C) (China). The outlook of these Credit Ratings (ratings) is stable.
The ratings reflect Ping An P&C's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, favourable business profile and appropriate enterprise risk management.
Ping An P&C's balance sheet strength assessment is underpinned by its risk-adjusted capitalisation at the strongest level, as measured by Best's Capital Adequacy Ratio (BCAR). The company has maintained steady growth in its consolidated capital and surplus (C&S) over the last decade. By the end of 2024, its C&S was RMB 136.7 billion (USD 18.7 billion), a 9.0% growth from the prior year. Its investment portfolio maintains steady growth in 2024, continuing to consist of mainly fixed-income assets. Ping An P&C's financial flexibility is proven by its track record of issuing capital supplementary bonds in domestic debt markets. The issuance also enhances the company's solvency position.
Ping An P&C's operating performance is assessed as strong. The company has consistently delivered a double-digit return on equity (ROE) over the last decade, except for 2022 and 2023, due to unfavorable underwriting experience. In 2024, ROE recovered to 11.5% with a net profit after tax of RMB 15.0 billion. Given the company's size and domicile, its underwriting profitability is better than the domestic peer average. The motor line remains a significant source of its insurance service revenue and underwriting profit. Despite increasing premium proportion from new-energy vehicle (NEV) policies due to escalating new NEV sales in domestic market, leverage on its competitive edge including granular operating model and pricing techniques, Ping An P&C continues to deliver a stable underwriting margin in its motor book. The negative impact from the credit and guarantee line in 2022 and 2023, was considered one-off, and Ping An P&C has already ceased underwriting new policies since November 2023. The company's net income is also supported by its stable income from investments, interest and dividends, as well as realised and unrealised gains from investments.
Ping An P&C's favourable business profile is supported by its sizeable insurance portfolio, diversified distribution channels and geographic span in China, as well as its strong brand recognition. The company has been the second-largest property/casualty insurer in China since 2009, and has maintained a domestic market share of around 20% over the last decade, in terms of property/casualty direct premiums written. In 2024, its insurance service revenue reached RMB 328.1 billion. Despite relentless efforts to grow its non-motor lines, Ping An P&C remains well recognised in the domestic market for its motor insurance, which contributed around 70% of the company's top line for the last five years. Additionally, Ping An P&C's investment in new technologies has yielded positive outcomes, evidenced by improvements in operational efficiency and enhancements in risk management.
Ping An P&C is well-positioned at its current ratings level. Positive rating actions could occur if the company demonstrates a strengthening trend in its footprint in the global market, while maintaining its current balance sheet strength and solid operating performance. Positive action could also occur if the company demonstrates sustainable enhancement in its balance sheet strength. Negative rating actions could arise if there is a sustained deteriorating trend in Ping An P&C's underwriting and operating performance. Negative rating actions also could occur if the company's balance sheet strength were to weaken significantly, for example, due to materially heightened underwriting leverage or investment exposure to risky assets.
Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 minutes ago
- Business Wire
Ativion® and NASEF Partner to Expand Safe, Accessible Esports in K–12 Schools
NEW YORK--(BUSINESS WIRE)-- Ativion® and the Network of Academic and Scholastic Esports Federations (NASEF) have signed a partnership agreement to explore programs that will promote esports while making it easier for K-12 schools to safely access games and online resources. Through this collaboration, Ativion will work closely with NASEF's experts on several technical initiatives for StudentKeeper, powered by ContentKeeper, an all-in-one platform for content filtering, classroom management, and digital safety. The partnership aims to give schools easier, safer access to the games and communities that are important to academic esports leagues and clubs. Ativion and NASEF will also participate in joint scholastic esports promotion and training programs. 'We are pleased to join with NASEF to make it easier and safer for schools and leagues to offer scholastic esports programs,' said Tobias Hartmann, CEO of Ativion. Share NASEF is the leading global scholastic esports organization. NASEF supports leaders and youth to build career and professional skills through a unique blend of play and learning. Its frameworks for developing scholastic esports classes, clubs, and teams are used by tens of thousands of educators seeking to leverage the draw of gameplay for student impact. 'We are pleased to join with NASEF to make it easier and safer for schools and leagues to offer scholastic esports programs,' said Tobias Hartmann, CEO of Ativion. 'Scholastic esports is an all-inclusive sports program available to every student, and it offers many benefits, academically and socially. We look forward to working closely with NASEF to make StudentKeeper a conduit for schools to grow their scholastic esports programs.' 'School leaders and educators are eager to adopt scholastic esports because of its proven positive impacts on student attendance, grades, test scores, and morale. Of course, it is important that they can access key gaming and information sites without compromising the security of the network. NASEF and Ativion are working together to make that safe access a simpler process,' said Claire LaBeaux, Chief Advancement Officer for NASEF. StudentKeeper – which is built on Ativion's award winning ContentKeeper filtering and real-time reporting platform – was released this year as a single platform for schools and school districts. StudentKeeper gives school administrators confidence that their hardware and network can manage threats to data, privacy, and the well-being of their students. About Ativion Ativion, formerly Impero Solutions, is a global leader in EdTech, Cybersecurity, and Remote Access solutions. Founded on the belief that all children deserve access to a safe digital environment that promotes positive learning, Ativion is dedicated to helping drive learning engagement worldwide. Our flagship product, StudentKeeper, Powered by ContentKeeper, creates a secure and flexible digital learning environment, fostering a love of learning in every child. Ativion safeguards over 10 million students in 80 countries, serving more than 700 U.S. school districts. We are a trusted partner in education, providing innovative solutions that equip educators and empower students to thrive in a connected world. Follow Ativion on LinkedIn. About NASEF NASEF equips education, community, and industry leaders to maximize the potential of scholastic esports. As a non-profit, NASEF supports leaders and youth to develop career and professional skills through a unique blend of play and learning. Using its research-backed approach, NASEF guides organizations around the world striving to make impacts through scholastic esports. NASEF operates under the umbrella of the Worldwide Scholastic Esports Foundation, a 501(c)3 nonprofit headquartered in Atlanta, GA. The International Esports Federation has entrusted NASEF with training and supporting its 130+ member federations as they undertake development of scholastic esports programs. Find NASEF at and on LinkedIn.
Associated Press
7 minutes ago
- Associated Press
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025-- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on CONTACT: Media Contact Information: Ned Glascock E-mail:[email protected] Website: Morton E-mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM
Business Wire
11 minutes ago
- Business Wire
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
